References
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Global Health; Committee on Stronger Food and Drug Regulatory Systems Abroad. Stronger food and drug regulatory systems abroad. In: Woteki CE, Buckley GJ, editors. Washington (DC): National Academies Press (US); 2020. http://www.ncbi.nlm.nih.gov/books/NBK555797/. Accessed 19 Nov 2020.
- WHO. WHO essential medicines and health products: annual report 2017: towards access 2030. Geneva: World Health Organization; 2018. Report No.: WHO/EMP/2018.01. https://apps.who.int/iris/handle/10665/272972. Accessed 13 July 2020.
- Hafner T, Banda M, Kohler J, Babar Z-U-D, Lumpkin M, Adeyeye MC, et al. Integrating pharmaceutical systems strengthening in the current global health scenario: three “uncomfortable truths” J Pharm Policy Pract. 2020;13:38.
- WHO. WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems of medicines and vaccines. WHO. World Health Organization. http://www.who.int/medicines/regulation/benchmarking_tool_version_vi/en/. Accessed 19 Nov 2020.
- WHO. Health systems financing: the path to universal coverage. Geneva: World Health Organization; 2010. http://www.who.int/whr/2010/en/. Accessed 26 May 2020.
- Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries. JAMA Netw Open. 2018;1(4):e181662.
- WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017. http://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/. Accessed 26 May 2020.
- WHO. Tracking universal health coverage: 2017 Global Monitoring Report. Geneva: World Health Organization; 2017. http://www.who.int/healthinfo/universal_health_coverage/report/2017/en/. Accessed 26 May 2020.
- Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673.
- Arriola Peñalosa MA, Cavazos Cepeda R, Alanis Garza M, Lumpkin MM. Optimized medical product regulation in Mexico: a win-win for public and economic health. Ther Innov Regul Sci. 2017;51(6):744–750.
- Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet Lond Engl. 2017;389(10067):403–476.
- Yamagiwa TJ. The New Law on Medicines and its implementation. Geneva: World Health Organization; 2015. http://www.who.int/health_financing/documents/Efficiency_health_systems_El_Salvador/en/. Accessed 6 Aug 2020.
- Preston C, Chahal HS, Porrás A, Cargill L, Hinds M, Olowokure B, et al. Regionalization as an approach to regulatory systems strengthening: a case study in CARICOM member states. Rev Panam Salud Publica Pan Am J Public Health. 2016;39(5):262–268.